• White blood cell disorders

Fylnetra Generic Name & Formulations

General Description

Pegfilgrastim-pbbk (polyethylene glycol/filgrastim conjugate) 6mg/0.6mL; soln for SC inj; preservative-free.

Pharmacological Class

Granulocyte colony stimulating factor.

How Supplied

Single-dose prefilled syringe—1 (w. needle)


Mechanism of Action

Pegfilgrastim is a colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.

Fylnetra Indications


To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use

Not for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Fylnetra Dosage and Administration

Adults and Children

See full labeling. Do not give between 14 days before and 24 hours after chemotherapy. ≥45kg: 6mg SC once per chemotherapy cycle. Children (<10kg): 0.1mg/kg; (10–20kg): 1.5mg; (21–30kg): 2.5mg; (31–44kg): 4mg. Direct administration of prefilled syringe with doses <6mg is not recommended.

Fylnetra Contraindications

Not Applicable

Fylnetra Boxed Warnings

Not Applicable

Fylnetra Warnings/Precautions


Monitor for splenomegaly, splenic rupture, acute respiratory distress syndrome (ARDS); evaluate if fever, lung infiltrates, or respiratory distress occurs; discontinue if ARDS diagnosed. Permanently discontinue if serious allergic reactions develop. Sickle cell disorders; discontinue if sickle cell crisis occurs. Monitor for glomerulonephritis; consider dose reduction or interruption if treatment-related. Monitor CBCs, platelet counts during therapy. Discontinue if aortitis is suspected. Myeloid malignancies. Myelodysplasia. Monitor for MDS/AML in those with breast or lung cancer. Possible transient (+) bone imaging changes in nuclear imaging. Pregnancy. Nursing mothers.

Fylnetra Pharmacokinetics


Half-life: 15–80 hours.

Fylnetra Interactions

Not Applicable

Fylnetra Adverse Reactions

Adverse Reactions

Bone or extremity pain; anaphylaxis, ARDS, splenic rupture, glomerulonephritis, leukocytosis, aortitis, thrombocytopenia, capillary leak syndrome (monitor closely if occurs).

Fylnetra Clinical Trials

See Literature

Fylnetra Note

Not Applicable

Fylnetra Patient Counseling

See Literature